All the news articles and press releases in one place.

Search
Date / Time Source Ticker Company Sector Market Cap Announcement
18Jul18 16:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
18Jul18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
18Jul18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29Jun18 13:10 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 13:10 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29Jun18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
28Jun18 21:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
27Jun18 21:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
26Jun18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
18Jun18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
16Jun18 10:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15Jun18 07:40 GNW 0QLR:LON Novartis AG Health 208,186m Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
15Jun18 07:35 GNW 0QLR:LON Novartis AG Health 208,186m Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
15Jun18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
13Jun18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
07Jun18 21:05 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
03Jun18 14:00 GNW 0QLR:LON Novartis AG Health 208,186m Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
02Jun18 21:00 GNW 0QLR:LON Novartis AG Health 208,186m New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
01Jun18 13:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 13:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 12:44 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
01Jun18 12:40 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
01Jun18 12:40 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
30May18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
28May18 15:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
24May18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
18May18 00:18 GNW 0QLR:LON Novartis AG Health 208,186m Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
18May18 00:14 GNW 0QLR:LON Novartis AG Health 208,186m Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
17May18 14:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
16May18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
16May18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces changes to the Executive Committee
16May18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces changes to the Executive Committee
15May18 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis successfully completes acquisition of AveXis, Inc.
15May18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15May18 05:45 GNW 0QLR:LON Novartis AG Health 208,186m Novartis completes tender offer for all outstanding shares of AveXis, Inc.
11May18 23:24 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
07May18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
03May18 03:06 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
02May18 21:05 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
01May18 21:26 GNW 0QLR:LON Novartis AG Health 208,186m Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 21:26 GNW 0QLR:LON Novartis AG Health 208,186m Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis provides update on proposed acquisition of AveXis
01May18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis provides update on proposed acquisition of AveXis
30Apr18 21:10 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
30Apr18 21:05 GNW 0QLR:LON Novartis AG Health 208,186m New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
25Apr18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
20Apr18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
19Apr18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered a strong first quarter and acted to become a more focused medicines company
19Apr18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered a strong first quarter and acted to become a more focused medicines company
18Apr18 21:01 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
17Apr18 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
17Apr18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17Apr18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis tender offer for AveXis commences
17Apr18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis tender offer for AveXis commences
16Apr18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
09Apr18 05:45 GNW 0QLR:LON Novartis AG Health 208,186m Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
09Apr18 05:45 GNW 0QLR:LON Novartis AG Health 208,186m Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
04Apr18 16:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
28Mar18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
27Mar18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
27Mar18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
23Mar18 12:51 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
22Mar18 23:30 GNW 0QLR:LON Novartis AG Health 208,186m Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
22Mar18 16:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
20Mar18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
12Mar18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m NOVARTIS FINANCE S.A. : Directorate change
12Mar18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces changes to the Executive Committee to support strategic priorities
07Mar18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis expands alliance with Science 37 to advance virtual clinical trials program
06Mar18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Xolair® recommended in new global chronic urticaria guideline
02Mar18 12:22 GNW 0QLR:LON Novartis AG Health 208,186m Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
01Mar18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
22Feb18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
16Feb18 21:05 GNW 0QLR:LON Novartis AG Health 208,186m Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
16Feb18 21:05 GNW 0QLR:LON Novartis AG Health 208,186m Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
14Feb18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis forms alliance to develop medicines for treating infectious diarrheal disease
13Feb18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
08Feb18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
01Feb18 21:05 GNW 0QLR:LON Novartis AG Health 208,186m Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
01Feb18 21:05 GNW 0QLR:LON Novartis AG Health 208,186m Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
31Jan18 22:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
26Jan18 18:02 GNW 0QLR:LON Novartis AG Health 208,186m Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26Jan18 18:02 GNW 0QLR:LON Novartis AG Health 208,186m Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
24Jan18 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
24Jan18 18:02 GNW 0QLR:LON Novartis AG Health 208,186m NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
24Jan18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24Jan18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
22Jan18 21:35 GNW 0QLR:LON Novartis AG Health 208,186m Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
22Jan18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
18Jan18 10:30 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
17Jan18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
16Jan18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
16Jan18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
11Jan18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis appoints Elizabeth Barrett as Oncology Head
11Jan18 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis appoints Elizabeth Barrett as Oncology Head
09Jan18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
04Jan18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
03Jan18 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Date / Time Source Company % Chg
18Jul18 16:30 GNW Novartis AG 0.70%
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
18Jul18 06:00 GNW Novartis AG 0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
18Jul18 06:00 GNW Novartis AG 0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29Jun18 13:10 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 13:10 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 06:00 GNW Novartis AG 0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29Jun18 06:00 GNW Novartis AG 0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
28Jun18 21:30 GNW Novartis AG 0.70%
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
27Jun18 21:30 GNW Novartis AG 0.70%
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
26Jun18 06:15 GNW Novartis AG 0.70%
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
18Jun18 06:15 GNW Novartis AG 0.70%
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
16Jun18 10:30 GNW Novartis AG 0.70%
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15Jun18 07:40 GNW Novartis AG 0.70%
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
15Jun18 07:35 GNW Novartis AG 0.70%
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
15Jun18 06:15 GNW Novartis AG 0.70%
Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
13Jun18 06:15 GNW Novartis AG 0.70%
Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
07Jun18 21:05 GNW Novartis AG 0.70%
Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
03Jun18 14:00 GNW Novartis AG 0.70%
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
02Jun18 21:00 GNW Novartis AG 0.70%
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
01Jun18 13:00 GNW Novartis AG 0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 13:00 GNW Novartis AG 0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 12:44 GNW Novartis AG 0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
01Jun18 12:40 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
01Jun18 12:40 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
30May18 06:15 GNW Novartis AG 0.70%
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
28May18 15:30 GNW Novartis AG 0.70%
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
24May18 06:00 GNW Novartis AG 0.70%
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
18May18 00:18 GNW Novartis AG 0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
18May18 00:14 GNW Novartis AG 0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
17May18 14:00 GNW Novartis AG 0.70%
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
16May18 06:15 GNW Novartis AG 0.70%
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
16May18 06:00 GNW Novartis AG 0.70%
Novartis announces changes to the Executive Committee
16May18 06:00 GNW Novartis AG 0.70%
Novartis announces changes to the Executive Committee
15May18 21:00 GNW Novartis AG 0.70%
Novartis successfully completes acquisition of AveXis, Inc.
15May18 06:15 GNW Novartis AG 0.70%
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15May18 05:45 GNW Novartis AG 0.70%
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
11May18 23:24 GNW Novartis AG 0.70%
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
07May18 06:15 GNW Novartis AG 0.70%
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
03May18 03:06 GNW Novartis AG 0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
02May18 21:05 GNW Novartis AG 0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
01May18 21:26 GNW Novartis AG 0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 21:26 GNW Novartis AG 0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 06:00 GNW Novartis AG 0.70%
Novartis provides update on proposed acquisition of AveXis
01May18 06:00 GNW Novartis AG 0.70%
Novartis provides update on proposed acquisition of AveXis
30Apr18 21:10 GNW Novartis AG 0.70%
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
30Apr18 21:05 GNW Novartis AG 0.70%
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
25Apr18 06:15 GNW Novartis AG 0.70%
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
20Apr18 06:15 GNW Novartis AG 0.70%
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
19Apr18 06:15 GNW Novartis AG 0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:15 GNW Novartis AG 0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:00 GNW Novartis AG 0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
19Apr18 06:00 GNW Novartis AG 0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
18Apr18 21:01 GNW Novartis AG 0.70%
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
17Apr18 21:00 GNW Novartis AG 0.70%
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
17Apr18 06:15 GNW Novartis AG 0.70%
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17Apr18 06:00 GNW Novartis AG 0.70%
Novartis tender offer for AveXis commences
17Apr18 06:00 GNW Novartis AG 0.70%
Novartis tender offer for AveXis commences
16Apr18 06:15 GNW Novartis AG 0.70%
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
09Apr18 05:45 GNW Novartis AG 0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
09Apr18 05:45 GNW Novartis AG 0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
04Apr18 16:00 GNW Novartis AG 0.70%
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
28Mar18 06:15 GNW Novartis AG 0.70%
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
27Mar18 06:00 GNW Novartis AG 0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
27Mar18 06:00 GNW Novartis AG 0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
23Mar18 12:51 GNW Novartis AG 0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
22Mar18 23:30 GNW Novartis AG 0.70%
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
22Mar18 16:30 GNW Novartis AG 0.70%
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
20Mar18 06:15 GNW Novartis AG 0.70%
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
12Mar18 06:00 GNW Novartis AG 0.70%
NOVARTIS FINANCE S.A. : Directorate change
12Mar18 06:00 GNW Novartis AG 0.70%
Novartis announces changes to the Executive Committee to support strategic priorities
07Mar18 06:15 GNW Novartis AG 0.70%
Novartis expands alliance with Science 37 to advance virtual clinical trials program
06Mar18 06:15 GNW Novartis AG 0.70%
Novartis' Xolair® recommended in new global chronic urticaria guideline
02Mar18 12:22 GNW Novartis AG 0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
01Mar18 06:15 GNW Novartis AG 0.70%
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
22Feb18 06:15 GNW Novartis AG 0.70%
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
16Feb18 21:05 GNW Novartis AG 0.70%
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
16Feb18 21:05 GNW Novartis AG 0.70%
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
14Feb18 06:15 GNW Novartis AG 0.70%
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
13Feb18 06:15 GNW Novartis AG 0.70%
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
08Feb18 06:15 GNW Novartis AG 0.70%
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
01Feb18 21:05 GNW Novartis AG 0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
01Feb18 21:05 GNW Novartis AG 0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
31Jan18 22:00 GNW Novartis AG 0.70%
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
26Jan18 18:02 GNW Novartis AG 0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26Jan18 18:02 GNW Novartis AG 0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
24Jan18 21:00 GNW Novartis AG 0.70%
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
24Jan18 18:02 GNW Novartis AG 0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
24Jan18 06:00 GNW Novartis AG 0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24Jan18 06:00 GNW Novartis AG 0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
22Jan18 21:35 GNW Novartis AG 0.70%
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
22Jan18 06:00 GNW Novartis AG 0.70%
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
18Jan18 10:30 GNW Novartis AG 0.70%
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
17Jan18 06:15 GNW Novartis AG 0.70%
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
16Jan18 06:15 GNW Novartis AG 0.70%
Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
16Jan18 06:00 GNW Novartis AG 0.70%
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
11Jan18 06:00 GNW Novartis AG 0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
11Jan18 06:00 GNW Novartis AG 0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
09Jan18 06:15 GNW Novartis AG 0.70%
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
04Jan18 06:15 GNW Novartis AG 0.70%
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
03Jan18 06:15 GNW Novartis AG 0.70%
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Date / Time Company % Chg
18Jul18 16:30 Novartis AG 0.70%
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
18Jul18 06:00 Novartis AG 0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
18Jul18 06:00 Novartis AG 0.70%
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29Jun18 13:10 Novartis AG 0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 13:10 Novartis AG 0.70%
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29Jun18 06:00 Novartis AG 0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29Jun18 06:00 Novartis AG 0.70%
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
28Jun18 21:30 Novartis AG 0.70%
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
27Jun18 21:30 Novartis AG 0.70%
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
26Jun18 06:15 Novartis AG 0.70%
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
18Jun18 06:15 Novartis AG 0.70%
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
16Jun18 10:30 Novartis AG 0.70%
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15Jun18 07:40 Novartis AG 0.70%
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
15Jun18 07:35 Novartis AG 0.70%
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
15Jun18 06:15 Novartis AG 0.70%
Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
13Jun18 06:15 Novartis AG 0.70%
Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
07Jun18 21:05 Novartis AG 0.70%
Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
03Jun18 14:00 Novartis AG 0.70%
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
02Jun18 21:00 Novartis AG 0.70%
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
01Jun18 13:00 Novartis AG 0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 13:00 Novartis AG 0.70%
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
01Jun18 12:44 Novartis AG 0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
01Jun18 12:40 Novartis AG 0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
01Jun18 12:40 Novartis AG 0.70%
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
30May18 06:15 Novartis AG 0.70%
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
28May18 15:30 Novartis AG 0.70%
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
24May18 06:00 Novartis AG 0.70%
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
18May18 00:18 Novartis AG 0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
18May18 00:14 Novartis AG 0.70%
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
17May18 14:00 Novartis AG 0.70%
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
16May18 06:15 Novartis AG 0.70%
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
16May18 06:00 Novartis AG 0.70%
Novartis announces changes to the Executive Committee
16May18 06:00 Novartis AG 0.70%
Novartis announces changes to the Executive Committee
15May18 21:00 Novartis AG 0.70%
Novartis successfully completes acquisition of AveXis, Inc.
15May18 06:15 Novartis AG 0.70%
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15May18 05:45 Novartis AG 0.70%
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
11May18 23:24 Novartis AG 0.70%
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
07May18 06:15 Novartis AG 0.70%
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
03May18 03:06 Novartis AG 0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
02May18 21:05 Novartis AG 0.70%
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
01May18 21:26 Novartis AG 0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 21:26 Novartis AG 0.70%
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
01May18 06:00 Novartis AG 0.70%
Novartis provides update on proposed acquisition of AveXis
01May18 06:00 Novartis AG 0.70%
Novartis provides update on proposed acquisition of AveXis
30Apr18 21:10 Novartis AG 0.70%
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
30Apr18 21:05 Novartis AG 0.70%
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
25Apr18 06:15 Novartis AG 0.70%
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
20Apr18 06:15 Novartis AG 0.70%
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
19Apr18 06:15 Novartis AG 0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:15 Novartis AG 0.70%
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19Apr18 06:00 Novartis AG 0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
19Apr18 06:00 Novartis AG 0.70%
Novartis delivered a strong first quarter and acted to become a more focused medicines company
18Apr18 21:01 Novartis AG 0.70%
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
17Apr18 21:00 Novartis AG 0.70%
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
17Apr18 06:15 Novartis AG 0.70%
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17Apr18 06:00 Novartis AG 0.70%
Novartis tender offer for AveXis commences
17Apr18 06:00 Novartis AG 0.70%
Novartis tender offer for AveXis commences
16Apr18 06:15 Novartis AG 0.70%
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
09Apr18 05:45 Novartis AG 0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
09Apr18 05:45 Novartis AG 0.70%
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
04Apr18 16:00 Novartis AG 0.70%
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
28Mar18 06:15 Novartis AG 0.70%
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
27Mar18 06:00 Novartis AG 0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
27Mar18 06:00 Novartis AG 0.70%
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
23Mar18 12:51 Novartis AG 0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
22Mar18 23:30 Novartis AG 0.70%
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
22Mar18 16:30 Novartis AG 0.70%
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
20Mar18 06:15 Novartis AG 0.70%
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
12Mar18 06:00 Novartis AG 0.70%
NOVARTIS FINANCE S.A. : Directorate change
12Mar18 06:00 Novartis AG 0.70%
Novartis announces changes to the Executive Committee to support strategic priorities
07Mar18 06:15 Novartis AG 0.70%
Novartis expands alliance with Science 37 to advance virtual clinical trials program
06Mar18 06:15 Novartis AG 0.70%
Novartis' Xolair® recommended in new global chronic urticaria guideline
02Mar18 12:22 Novartis AG 0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
01Mar18 06:15 Novartis AG 0.70%
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
22Feb18 06:15 Novartis AG 0.70%
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
16Feb18 21:05 Novartis AG 0.70%
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
16Feb18 21:05 Novartis AG 0.70%
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
14Feb18 06:15 Novartis AG 0.70%
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
13Feb18 06:15 Novartis AG 0.70%
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
08Feb18 06:15 Novartis AG 0.70%
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
01Feb18 21:05 Novartis AG 0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
01Feb18 21:05 Novartis AG 0.70%
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
31Jan18 22:00 Novartis AG 0.70%
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
26Jan18 18:02 Novartis AG 0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26Jan18 18:02 Novartis AG 0.70%
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
24Jan18 21:00 Novartis AG 0.70%
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
24Jan18 18:02 Novartis AG 0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
24Jan18 06:00 Novartis AG 0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24Jan18 06:00 Novartis AG 0.70%
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
22Jan18 21:35 Novartis AG 0.70%
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
22Jan18 06:00 Novartis AG 0.70%
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
18Jan18 10:30 Novartis AG 0.70%
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
17Jan18 06:15 Novartis AG 0.70%
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
16Jan18 06:15 Novartis AG 0.70%
Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
16Jan18 06:00 Novartis AG 0.70%
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
11Jan18 06:00 Novartis AG 0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
11Jan18 06:00 Novartis AG 0.70%
Novartis appoints Elizabeth Barrett as Oncology Head
09Jan18 06:15 Novartis AG 0.70%
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
04Jan18 06:15 Novartis AG 0.70%
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
03Jan18 06:15 Novartis AG 0.70%
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer